Molbio Diagnostics Q2 FY27: PAT ₹52.74 & Rev ₹411.48 Cr

Investor Takeaways

Revenue grew to ₹411.48 Cr from ₹100.47 Cr YoY, driven by strong test-kit volume growth.

EBITDA turned positive at ₹103.68 Cr compared to a ₹14.50 Cr loss in the prior year.

PAT improved to ₹52.74 Cr from a ₹23.94 Cr loss, reflecting margin expansion and operational efficiency.

OPM increased to 20.45% in Q1FY27 from -27.66% in Q1FY26, indicating improved cost control.

⚠️ No specific risks identified in this filing.

Overall Tone: Positive based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹411.48 Cr	+311.5%
Net Profit	₹52.74 Cr	+321.7%
EBITDA	₹103.68 Cr	+814.5%
EPS	₹5.21	+321.7%
OPM	20.45%	+48.11 pp

What Changed

The company demonstrated a significant turnaround in profitability. Revenue increased more than fourfold to ₹411.48 Cr from ₹100.47 Cr YoY, primarily due to strong volume growth in Truenat test kits. EBITDA shifted decisively from a ₹14.50 Cr loss to a ₹103.68 Cr profit, reflecting improved operational efficiency and cost management. Net profit followed suit, moving from a ₹23.94 Cr loss to ₹52.74 Cr profit, supported by higher margins and scale-driven economies. The operating profit margin expanded to 20.45% from -27.66% in the same quarter last year, underscoring progress in converting revenue into sustainable earnings. These improvements occurred without any new capital expenditure, indicating that the current infrastructure is scaling effectively with existing resources.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Molbio Diagnostics Ltd (MOLBIO)	Not available	Not available	Not available	12,720.46
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	37.69	14.57%	18.72%	4,55,825.66
Divis Laboratories Ltd (DIVISLAB)	84.43	17.45%	23.04%	2,47,018.51
Torrent Pharmaceuticals Ltd (TORNTPHARM)	78.37	25.7%	15.1%	1,86,874.73

Molbio’s valuation metrics are not directly comparable to peers due to its smaller scale and profitability stage. However, its P/B ratio of 10.88 suggests market expectations of future growth, which is higher than the sector’s typical value orientation.

Risks & Concerns

No specific risks identified in this filing.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q1FY27	408.38	52.74	20.45
Q4FY26	560.62	95.83	24.82
Q1FY26	99.71	-23.94	-27.66

📄 View Original Announcement (PDF)

📊 Stock Analysis — MOLBIO ✨ Ask AI About This

About Molbio Diagnostics Ltd (MOLBIO)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹16,255.48 Cr

View full MOLBIO stock details →

📡 Get AI alerts when MOLBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MOLBIO — Free

💡 Ask AI about this filing

"How does ₹57 Cr deferred export revenue impact full-year guidance?" "What is the expected timeline for new assay launches in oncology?" "What is the projected cash flow run rate post-R&D facility completion?"

Ask AI Free →

📊 More MOLBIO filings

See all MOLBIO filings →

🔥 Also filed on 7 September 2026

521036 Source Industries (India) Ltd Annual Report 543578 Olatech Solutions Ltd Annual Report 512025 Asgard Alcobev Ltd Annual Report SIGACHI Sigachi Industries Ltd Corporate Action 503675 Wagend Infra Venture Ltd Annual Report 542864 Mount Housing & Infrastructure Ltd Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MOLBIO files new disclosures

Track MOLBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.